Tiltan Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://tiltanpharma.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT01659502
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT01509911
- Locations
- 🇺🇸
Emory Clinic, Atlanta, Georgia, United States
🇺🇸White Plains Hospital, White Plains, New York, United States
🇮🇱HaEmek Medical Center, Afula, Israel
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase 2
- Conditions
- Metastatic Castration Resistant Prostate Cancer (CRPC)
- Interventions
- Drug: Hamsa-1™ TL-118
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT00684970
- Locations
- 🇮🇱
Bnei Tzion Medical Center, Haifa, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
🇮🇱Sheba Medical Center, Tel Hashomer, Israel
News
No news found